Syndax Pharmaceuticals Inc·4/A

Mar 25, 4:03 PM ET

Meyers Michael L. 4/A

4/A · Syndax Pharmaceuticals Inc · Filed Mar 25, 2019

Insider Transaction Report

Form 4/AAmended
Period: 2019-03-21
Meyers Michael L.
SVP, Chief Development Officer
Transactions
  • Purchase

    Common Stock

    2019-03-21$4.87/sh+8$397,230 total
Footnotes (1)
  • [F1]Amendment filed to correct previously filed Form, which did not include 8 shares purchased in an additional transaction.

Documents

1 file
  • 4
    primarydocument.xml

    PRIMARY DOCUMENT